DHR Danaher Corporation
FY2025 10-K
Danaher Corporation (DHR) filed its fiscal year 2025 10-K annual report with the SEC on Feb 24, 2026. This page provides AI-powered analysis of the filing, including business overview, management discussion, risk factors, and key financial metrics from XBRL data.
AI Filing AnalysisFY2025 10-K
Business Overview
- • Global science/technology platform across Biotechnology, Life Sciences, and Diagnostics segments; high recurring-revenue model via consumables and direct sales in ~50 countries
- • ~60,000 employees (associates) as of Dec 31, 2025; ~22,000 in North America, ~20,000 Western Europe, ~15,000 high-growth markets
Management Discussion & Analysis
- • Revenue $24.6B, up 3.0% YoY; core sales +2.0% driven by Biotechnology (+6.5% core) and Diagnostics (+1.5% core), offset by Life Sciences (-1.5% core)
- • Operating margin 19.1% vs 20.4%; gross margin 59.1% vs 59.5%; SG&A 33.5% vs 32.5% of sales, pressured by $533M impairment charges
Risk Factors
- • IEEPA tariff authority struck down by U.S. Supreme Court Feb 2026; administration pursuing new tariffs under alternative authority — full impact still uncertain
- • ~59% of 2025 sales from outside U.S.; China alone ~11% of sales, with government-mandated volume-based procurement programs actively suppressing prices
Financial SummaryXBRL
Revenue
$24.6B
Net Income
$3.6B
Gross Margin
59.1%
Operating Margin
19.1%
Net Margin
14.7%
ROE
6.9%
Total Assets
$83.5B
EPS (Diluted)
$5.05
Operating Cash Flow
$6.4B
Source: XBRL data from Danaher Corporation FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on Danaher Corporation
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.